



For further information:
Marta Campos Martínez
mcampos@rovi.es
Tel: +34 91 244 44 22

ROVI signs a contract with Farmalíder for the manufacturing of oral forms

Madrid, 28th January, 2011 – Laboratorios Farmacéuticos Rovi, S.A. ("ROVI" or the "Company") announces today that it has signed a contract with Farmalíder, a pharmaceutical company that specialises in the development of branded products, OTC pharmaceutical products that are available without prescription, products with added value, and generic products, for the manufacturing, research and conditioning of pharmaceutical specialties based on Ibuprofen and Paracetamol.

ROVI has been authorised by the Spanish Agency for Medicines and Medical Devices (AEMPS) for the manufacturing of these products.

According to the terms of the contract, ROVI will provide manufacturing, research and conditioning services to Farmalíder for a period of eight years. In addition, Farmalíder has undertaken to work towards providing ROVI with annual manufacturing that could represent an increase in the production of the plant of Frosst Ibérica, S.A. by 10% to 15%.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, said: *"we are very happy to be working with Farmalíder, our first client in the area of manufacturing oral forms, apart from MSD, as this will contribute to realizing the economic potential of the infrastructure that we have acquired, and provide us with an opportunity for sustained and profitable growth in the long term."*

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 27 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI's research and development pipeline is focused primarily on addressing currently unmet medical needs by developing new LMWH-based products and expanding applications for its existing LMWH-based products. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. Additional information about ROVI is available on the company's website: www.rovi.es